The latest news about Lumendi
Demonstrating Significant Time and Cost Savings in Colorectal ESD
DiLumen Reduced Total Procedure Time by 36.5%, Leading to an Average Cost Savings of $610.16 Per Patient and Improved En Bloc Resection Rate to 97.2%
EZ¹ successfully completes Customer Evaluation phase.
A Randomized Prospective Study Evaluating Effectiveness Of A Double Balloon Endolumenal Platform For Colorectal EndoscopicSubmucosal Dissection
Endoscopic removal of colonic polyps and early cancers eliminates the need for surgical resection and possible temporary or permanent colostomy.
Dr. Roberta Maselli, receives innovation of the year award for the best new device from the ESGE
Lumendi Receives 510(k) Clearance for Two New Devices
Lumendi, LLC has received U.S. Food and Drug Administration (FDA) 510(k) clearance for DiLumen EZ¹, a single-use, disposable endotherapy device for endoscopic mucosal resections (EMR) and difficult colonoscopies.
Lumendi Files for 510(k) Clearance for Two New Products
Lumendi Reports Successful Completion Of Dilumen™ Eip First-in-human Trials
EZ Glide Pushes Lumendi to New Quarter-Over-Quarter Sales Record
Lumendi Introduces EZ Glide Hydrophilic Coating for Its DiLumen Endoluminal Interventional Platform (EIP™)
DiLumen online
ASGE Webinar Online
PIONEERING ENDOSURGERY NEW MISSION STATEMENT AT LUMENDI
Pioneering Endosurgery reflects Lumendi’s innovative, three-part pathway to:
expand indication areas and procedures in the upper gastrointestinal tract, which includes a recent submission to the FDA;
innovate improvements planned for the DiLumen EIP, including a proprietary lubricated inner surface of DiLumen’s sheath for better endoscope handling performance; and
commercially release the DiLumen C2 platform[1] to bring robotic-like end-effectors to endolumenal surgery in a low-cost, disposable format to provide endoscopists with unprecedented control of tissue.
LUMENDI REPORTS FIRST INCISIONLESS APPENDECTOMY USING DOUBLE-BALLOON ENDOLUMENAL INTERVENTIONAL PLATFORM
Dr. Kantsevoy states, “Endoscopic endolumenal appendectomy is less invasive than traditional surgical, laparoscopic, transvaginal or transgastric appendectomy.
Early Trial Data Show Promise in Endoscopic Procedure Time Study
A study evaluating endoscopic procedure time removing complex colorectal polyps shows superiority of Lumendi’s DiLumen device over a control group.
LUMENDI OPERATIONS AND CLINICAL SUPPORT REMAIN AVAILABLE DURING OBSERVANCE OF COVID-19 PRECAUTIONS.
We have adapted our operation and clinical support models as healthcare facilities prioritize focus on patients affected by COVID-19.
LUMENDI REPORTS SUCCESSFUL ENROLLMENT CLOSURE OF ITS DILUMEN™ ENDOLUMENAL INTERVENTIONAL PLATFORM (EIP™) STUDY
The study evaluates DiLumen’s effect on endoscopic procedure time for pre-cancerous colorectal complex polypectomies.
LARGE COMPLEX POLYPS REMOVED SUCCESSFULLY FROM THREE PATIENTS WITHOUT SURGICAL INTERVENTION USING LUMENDI DILUMEN C2™
The first successful case at Cleveland Clinic using DiLumen C2 was completed by Dr. Gorgun when a large complex polyp in the distal sigmoid, 18cm from the anus was removed from a 72-year-old woman with a narrow sigmoid.
LUMENDI RECEIVES 510(k) CLEARANCE FOR DILUMEN Ik™ ENDOLUMENAL INTERVENTIONAL KNIFE
LUMENDI BRANDS EXCLUSIVE TISSUE MANIPULATION FEATURE FOR COMPANY’S DILUMEN EIP
LUMENDI RECEIVES FDA 510(k) CLEARANCE FOR DILUMEN C2TM
LUMENDI RECEIVES FDA 510(k) CLEARANCE FOR INNOVATIVE DILUMEN™ EIP DEVICE MODIFICATION TO IMPROVE TISSUE RETRACTION DURING THERAPEUTIC ENDOSCOPY
With recent regulatory approvals in Europe, Lumendi has established distribution in the UK, France and Italy and has conducted successful procedures with clinicians in each country.
500 THERAPEUTIC PROCEDURES USING DILUMEN™ EIP COMPLETED ACROSS U.S., EUROPE AND ASIA
LUMENDI EXPANDS TEAM WITH NEW VP OF SALES, MICHAEL R. THOMAS
LUMENDI OPENS EU MARKET FOR DILUMEN EIP™
FLEXIBLE ENDOSCOPIC DOUBLE BALLOON PLATFORM: FROM CONCEPT TO HUMAN FEASIBILITY TRIAL
LUMENDI RECEIVES FDA 510(k) CLEARANCE FOR DILUMEN Is™ ENDOLUMENAL INTERVENTIONAL SCISSORS
LUMENDI RECEIVES FDA 510(k) CLEARANCE FOR DILUMEN C2TM
DILUMEN™ EIP COMPLETES 100 THERAPEUTIC PROCEDURES ACROSS UNITED STATES
LUMENDI REPORTS SUCCESSFUL COMPLETION OF DILUMEN™ EIP FIRST-IN-HUMAN TRIALS
LUMENDI’S DILUMEN Ig™ ENDOLUMENAL INTERVENTIONAL GRASPER FOR MINIMALLY INVASIVE ENDOSCOPIC THERAPIES NOW AVAILABLE IN U.S.
LUMENDI EXPANDS MEDICAL ADVISORY BOARD WITH THREE GLOBAL EXPERTS IN ADVANCED ENDOSCOPY
LUMENDI EXPANDS SOCIAL MEDIA PRESENCE
LUMENDI ACHIEVES ISO 13485 CERTIFICATION FOR ITS MEDICAL DEVICES
LUMENDI DILUMEN™ EIP NOW AVAILABLE FOR ENDOLUMENAL THERAPY
MEDIA ALERT: PHOTO & VIDEO OPPORTUNITIES
DILUMEN™ ENDOLUMENAL INTERVENTION PLATFORM DEMONSTRATED IN WET AND DRY LABS AT DDW BOOTH #1808
DILUMEN™ ENDOLUMENAL INTERVENTION PLATFORM DEMONSTRATED IN WET AND DRY LABS AT DDW BOOTH #1808